CURE staff


Three Tenets to Prevent Stivarga-Related Side Effects, Improve Survival and Quality of Life

May 28, 2021

Although Stivarga may cause side effects after initial treatment, a dose escalation strategy and the preemptive use of steroid creams may help patients to tolerate the regimen better, while allowing them to capitalize on the agent’s survival benefit.

Know Your Lung Cancer: Accelerating Education and Access for Biomarker Testing

February 09, 2021

CURE will host a webinar, sponsored by Amgen, in which panelists from several cancer organizations will discuss ways to improve awareness around biomarker testing, improve coordination of care for patients with lung cancer and remove barriers to access to care.

Investigational Therapy Granted Breakthrough Designation for Lung Cancer Subset

December 21, 2020

The decision was based on data that demonstrated sotorasib induced anticancer activity and achieved a positive benefit-risk profile in patients with locally advanced or metastatic non-small cell lung cancer whose disease harbors a KRAS G12C mutation.

FDA Grants Novel Treatment for Acute Myeloid Leukemia Fast Track Designation

August 05, 2020

The FDA’s fast track designation for BST-236 to treat adults aged 75 years or older with acute myeloid leukemia, or who have comorbidities that prevent the use of intensive induction chemotherapy, may open the doors to an accelerated approval.